

the CFPB of subpart H of Regulation V (February 27, 2014 Notice <sup>1</sup>) and the FTC's associated PRA burden analysis. No comments were received. Pursuant to the OMB regulations, 5 CFR Part 1320, that implement the PRA, 44 U.S.C. 3501 et seq., the FTC is providing this second opportunity for public comment while seeking OMB approval to renew clearance for the FTC's calculated share of the associated PRA burden for the underlying disclosure requirements.

The burden figures below present estimates of the number of applicable motor vehicle dealers subject to the FTC's RBP Rule <sup>2</sup> and their assumed recurring disclosure burden, in addition to the estimated number of and burden for other entities over which the FTC shares enforcement burden with the CFPB under subpart H of Regulation V. For more details about the creditor notifications required and the basis for the calculations summarized below, see 79 FR 11108.

*Title:* Fair Credit Reporting Risk-Based Pricing Regulations.

*OMB Control Number:* 3084-0145.

*Type of Review:* Extension of currently approved collection.

*Estimated number of respondents:* 160,875.

*Estimated Annual Burden:* 9,652,500 hours and \$166,216,050 <sup>3</sup> in associated labor costs.

The FTC believes that the FTC and CFPB rules impose negligible capital or other non-labor costs, as the affected entities are likely to have the necessary supplies and/or equipment already (*e.g.*, offices and computers) for the information collections discussed above.

*Request for Comment:* You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before June 30, 2014. Write "RBP Rule, PRA Comment, P145403," on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including to the extent practicable, on the public

Commission Web site, at <http://www.ftc.gov/os/publiccomments.shtm>. As a matter of discretion, the Commission tries to remove individuals' home contact information from comments before placing them on the Commission Web site.

Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, like anyone's Social Security number, date of birth, driver's license number or other state identification number or foreign country equivalent, passport number, financial account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, like medical records or other individually identifiable health information. In addition, do not include any "[t]rade secret or any commercial or financial information which is . . . privileged or confidential" as provided in Section 6(f) of the FTC Act 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns devices, manufacturing processes, or customer names.

If you want the Commission to give your comment confidential treatment, you must file it in paper form, with a request for confidential treatment, and you have to follow the procedure explained in FTC Rule 4.9(c).<sup>4</sup> Your comment will be kept confidential only if the FTC General Counsel grants your request in accordance with the law and the public interest.

Postal mail addressed to the Commission is subject to delay due to heightened security screening. As a result, we encourage you to submit your comments online. To make sure that the Commission considers your online comment, you must file it at <https://ftcpublic.commentworks.com/ftc/rbprulepra2>, by following the instructions on the web-based form. If this Notice appears at <http://www.regulations.gov/#!/home>, you also may file a comment through that Web site.

If you file your comment on paper, write "RBP Rule, PRA Comment, P145403," on your comment and on the envelope, and mail or deliver it to the following address: Federal Trade

Commission, Office of the Secretary, Room H-113 (Annex J), 600 Pennsylvania Avenue NW., Washington, DC 20580. If possible, submit your paper comment to the Commission by courier or overnight service.

The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before June 30, 2014. You can find more information, including routine uses permitted by the Privacy Act, in the Commission's privacy policy, at <http://www.ftc.gov/ftc/privacy.htm>.

Comments on the information collection requirements subject to review under the PRA should additionally be submitted to OMB. If sent by U.S. mail, they should be addressed to Office of Information and Regulatory Affairs, Office of Management and Budget, Attention: Desk Officer for the Federal Trade Commission, New Executive Office Building, Docket Library, Room 10102, 725 17th Street NW., Washington, DC 20503. Comments sent to OMB by U.S. postal mail, however, are subject to delays due to heightened security precautions. Thus, comments instead should be sent by facsimile to (202) 395-5167.

**David C. Shonka,**

*Principal Deputy General Counsel.*

[FR Doc. 2014-12416 Filed 5-28-14; 8:45 am]

**BILLING CODE 6750-01-P**

---

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Chronic Fatigue Syndrome Advisory Committee

**AGENCY:** Office of the Secretary, Office of the Assistant Secretary for Health, Department of Health and Human Services (HHS)

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Chronic Fatigue Syndrome Advisory Committee (CFSAC) will hold a meeting. The meeting will be open to the public.

**DATES:** The meeting will be held on Monday, June 16, 2014, from 12:00 p.m. until 5:00 p.m., E.T. and Tuesday, June 17, 2014, from 9:00 a.m. until 5:00 p.m., E.T.

<sup>1</sup> 79 FR 11108.

<sup>2</sup> The FTC retains rulemaking authority for its RBP Rule solely for motor vehicle dealers described in section 1029(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act (Pub. L. 111-203, 124 Stat. 1376 (2010)) that are predominantly engaged in the sale and servicing of motor vehicles, the leasing and servicing of motor vehicles, or both.

<sup>3</sup> Bureau of Labor Statistics, Economic News Release, April 1, 2014, Table 1, "National employment and wage data from the Occupational Employment Statistics survey by occupation, May 2013": <http://www.bls.gov/news.release/ocwage.htm>. This is an update of the labor information used in the February 27, 2014 Notice. The newer table shows \$17.22 as the mean hourly wage for correspondence clerks.

<sup>4</sup> In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c), 16 CFR 4.9(c).

**ADDRESSES:** Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue SW., Great Hall, First Floor, Washington, DC 20201. For a map and directions to the Hubert H. Humphrey building, see <http://www.hhs.gov/about/hhh.html>.

**FOR FURTHER INFORMATION CONTACT:** Any questions about meeting registration or public comment sign-up should be directed to *CFSAC@seamoncorporation.com*.

Please direct other inquiries to *cfsac@hhs.gov*.

**SUPPLEMENTARY INFORMATION:** CFSAC was established on September 5, 2002 to advise, consult with, and make recommendations to the Secretary, through the Assistant Secretary for Health, on a broad range of topics including: (1) The current state of knowledge and research and the relevant gaps in knowledge and research about the epidemiology, etiologies, biomarkers, and risk factors relating to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and identifying potential opportunities in these areas; (2) impact and implications of current and proposed diagnosis and treatment methods for ME/CFS; (3) development and implementation of programs to inform the public, health care professionals, and the biomedical research communities about ME/CFS advances; and (4) strategies to improve the quality of life of ME/CFS patients.

The agenda for this meeting is being developed and will be posted on the CFSAC Web site, <http://www.hhs.gov/advcomcfs/> when finalized. The meeting will be live-video streamed at <http://www.hhs.gov/live> and archived through the CFSAC Web site: <http://www.hhs.gov/advcomcfs/>. Listening-only via telephone will be available on both days. Call-in information will be posted on the CFSAC Web site. Individuals who plan to attend in-person should register at <http://www.blsmetings.net/CFSAC>. All registration should be completed by June 12, 2014. Attendance by visitors who are not U.S. citizens is welcome, but prior approval is required by sending a request to *CFSAC@seamoncorporation.com* before June 5, 2014. Members of the media will also need to register. All attendees will be required to show valid government-issued picture identification (state or federal) for entry into the federal building. Non-federal employees will receive a wrist band that must be worn the entire time. Security requires all non-federal employees to be escorted the entire time they are in the building.

Upon leaving the building for any reason, persons will be required to follow the security steps mentioned above and receive a new wrist band.

Members of the public will have the opportunity to provide public comment at the meeting or via telephone. International calls cannot be accommodated. You are no longer required to submit a written copy of your testimony unless you wish to have it included in the public record. Individuals wishing to provide public comment in-person or via phone will be required to request time for public comment by Monday, June 9, 2014, at the following link: <http://www.blsmetings.net/CFSAC>. An email to acknowledge receipt of the request for public comment will be sent from *CFSAC@seamoncorporation.com*. Another email will be sent by June 12, 2014, to confirm the time that has been given to each individual who is scheduled to provide public comment. Each speaker will be limited to three minutes for public comment. No exceptions will be made. Priority will be given to individuals who have not provided public comment within the previous year.

Individuals wishing to submit written comment for the public record should send an electronic copy of their written testimony to: *CFSAC@seamoncorporation.com* by June 12, 2014. The document for public record must not exceed 5 single-spaced, typed pages, using a 12-point typeface; it is preferred that the document be prepared in the MS Word format. Please note that PDF files, handwritten notes, charts, and photographs will not be posted on the CFSAC Web site, but will be available upon request at *CFSAC@seamoncorporation.com* and for public view during the CFSAC meeting at the Hubert H. Humphrey Building, Department of Health and Human Services, 200 Independence Ave. SW., Great Hall, Washington, DC 20201.

Requests to participate in the public comment session and provide written testimony will not be accepted through the CFSAC email account. Please send all questions about specific public comment requests or inquiries to *CFSAC@seamoncorporation.com*.

Only written testimony submitted for public record and received in advance of the meeting are part of the official meeting record and will be posted to the CFSAC Web site. Materials submitted should not include sensitive personal information, such as social security number, birthdate, driver's license number, state identification or foreign country equivalent, passport number, financial account number, credit or

debit card number. If you wish to remain anonymous the document must specify this.

Persons who wish to distribute printed materials in person to CFSAC members should submit one copy to the Designated Federal Officer at *cfsac@hhs.gov*, prior to June 12, 2014.

Dated: May 16, 2014.

**Nancy C. Lee,**

*Designated Federal Officer, Chronic Fatigue Syndrome Advisory Committee.*

[FR Doc. 2014-12371 Filed 5-28-14; 8:45 am]

**BILLING CODE 4150-28-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Research Misconduct

**AGENCY:** Office of the Secretary, HHS.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Helen Freeman, Ph.D., Harvard Medical School and Beth Israel Deaconess Medical Center:* Based on an investigation conducted by Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center (BIDMS) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Helen Freeman, former HMS Postdoctoral Fellow at BIDMS, engaged in research misconduct in research supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grant R37 DK053477.

ORI found that the Respondent engaged in research misconduct by knowingly and intentionally falsifying three (3) figures and/or legends and one (1) supplemental movie legend in a manuscript submitted for publication to the journal *Nature* (Freeman, H.C., Kong, D., Sidman, R.L., & Lowell, B. "Inhibition of UCP2 Prevents Neurodegenerative Diseases in Mice.").

Specifically, ORI found that Respondent:

- Falsified Figure 6 and its legend in a manuscript submitted to *Nature* by claiming that the experiment represented histological and rotarod results from 5 week old *pcd3f<sup>-/-</sup>* mice treated with saline or *pcd3f<sup>-/-</sup>* mice treated with genipin when the genotype, treatment conditions, numbers of mice used, and mice age were not as claimed; these falsified data also were presented to a colleague for use in related experiments